BGI Genomics(SZ:300676) Sou Hu Cai Jing·2025-08-05 12:48Core Viewpoint - As of August 5, 2025, BGI Genomics (300676) reported a closing price of 53.34 yuan, experiencing a decline of 0.78% with a turnover rate of 1.89% and a trading volume of 78,500 lots, amounting to 418 million yuan in transaction value [1] Financial Performance - For the first quarter of 2025, BGI Genomics reported total operating revenue of 672 million yuan, a year-on-year decrease of 18.18% - The net profit attributable to shareholders was 52.695 million yuan, a year-on-year decrease of 524.87% - The non-recurring net profit was 63.297 million yuan, a year-on-year decrease of 2,879.13% - The current ratio was 2.854, the quick ratio was 2.617, and the debt-to-asset ratio was 26.68% [1] Capital Flow - On the reporting day, the net outflow of main funds was 27.6854 million yuan, accounting for 6.63% of the transaction value - The net outflow of large orders was 21.3134 million yuan, accounting for 5.1% of the transaction value, while the net outflow of medium orders was 25.4012 million yuan, accounting for 6.08% - Small orders saw a net inflow of 2.2842 million yuan, accounting for 0.55% of the transaction value [1] Company Overview - BGI Genomics, established in 2010 and located in Shenzhen, primarily engages in professional technical services - The company has a registered capital of 4.15821575 billion yuan and a paid-in capital of 3.26119339 billion yuan - The legal representative of the company is Zhao Lijian [1][2] Investment and Intellectual Property - BGI Genomics has made investments in 71 companies and participated in 42 bidding projects - The company holds 665 trademark registrations and 374 patents, along with 13 administrative licenses [2]